v3.26.1
Summary of Significant Accounting Policies - Schedule of Significant Segment Expenses (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Mar. 31, 2026
Jun. 30, 2025
Mar. 31, 2025
Jun. 30, 2026
Jun. 30, 2025
Segment Reporting [Line Items]            
Total operating expenses $ 22,869   $ 24,733   $ 44,050 $ 42,697
Loss from operations (22,869)   (24,733)   (44,050) (42,697)
Other income, net 862   1,224   1,980 2,633
Change in fair value of warrant liabilities (9,623)   12,293   (28,585) 22,353
Net loss (31,630) $ (39,025) (11,216) $ (6,495) (70,655) (17,711)
Operating Segments [Member]            
Segment Reporting [Line Items]            
Tegoprubart - kidney transplantation programs 5,692   8,705   11,106 17,237
Tegoprubart - other development programs 0   0   0 (168)
Manufacturing 7,161   7,626   14,947 9,295
Personnel-related expenses 4,095   3,697   7,898 7,144
Stock-based compensation 3,154   2,694   5,356 5,558
Other segment items 2,767   2,011   4,743 3,631
Total operating expenses 22,869   24,733   44,050 42,697
Loss from operations (22,869)   (24,733)   (44,050) (42,697)
Other income, net 862   1,224   1,980 2,633
Change in fair value of warrant liabilities (9,623)   12,293   (28,585) 22,353
Net loss $ (31,630)   $ (11,216)   $ (70,655) $ (17,711)